Neurocrine Biosciences
NBIX
594 hedge funds and large institutions have $12.9B invested in Neurocrine Biosciences in 2024 Q2 according to their latest regulatory filings, with 80 funds opening new positions, 254 increasing their positions, 188 reducing their positions, and 68 closing their positions.
134% more call options, than puts
Call options by funds: $125M | Put options by funds: $53.6M
35% more repeat investments, than reductions
Existing positions increased: 254 | Existing positions reduced: 188
18% more first-time investments, than exits
New positions opened: 80 | Existing positions closed: 68
1% more funds holding
Funds holding: 589 → 594 (+5)
0% more capital invested
Capital invested by funds: $12.9B → $12.9B (+$12.4M)
0.83% less ownership
Funds ownership: 94.01% → 93.18% (-0.83%)
11% less funds holding in top 10
Funds holding in top 10: 9 → 8 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$84.8M |
| 2 |
Caisse de Depot et Placement du Quebec (CDPQ)
Montreal,
Quebec, Canada
|
+$69.2M |
| 3 |
1832 Asset Management
Toronto,
Ontario, Canada
|
+$69.2M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
+$63.3M |
| 5 |
BlackRock
New York
|
+$58.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$115M |
| 2 |
VPC
Vestal Point Capital
New York
|
-$97.9M |
| 3 |
Morgan Stanley
New York
|
-$71.4M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
-$55.9M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$48.9M |
NBIX Hedge Fund Activity: Q2 2024 in Review
594 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q2 2024, worth a combined $12.9B — up 0.1% from $12.9B a quarter earlier.
Buyers outnumbered sellers: 80 funds opened new NBIX positions and 68 closed out — a net gain of 12 holders — while 254 added to existing stakes and 188 trimmed.
The largest buyer was State Street, adding an estimated $84.8M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $115M sold.
- 594 institutional investors held Neurocrine Biosciences (NBIX) as of Q2 2024, up from 589 in Q1 2024.
- Funds reported $12.9B of Neurocrine Biosciences stock for Q2 2024, up 0.1% quarter-over-quarter.
- 80 funds opened new Neurocrine Biosciences positions in Q2 2024 and 68 closed out, a net change of +12 holders.
- The largest Neurocrine Biosciences buyer in Q2 2024 was State Street, an estimated $84.8M added.
- The largest Neurocrine Biosciences seller in Q2 2024 was Point72 Asset Management, an estimated $115M sold.
Based on aggregated 13F filings for Q2 2024.